1 week Ago By ABMN Staff
CIBC Asset Management Inc grew its holdings in shares of Exact Sciences Co. ( NASDAQ:EXAS – Free Report ) by 6.2% in the second quarter, HoldingsChannel reports.
The fund owned 6,118 shares of the medical research company’s stock after purchasing an additional 356 shares during the quarter. CIBC Asset Management Inc’s holdings in Exact Sciences were worth $258,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Several other hedge funds and other institutional investors have also recently modified their holdings of EXAS.
Truist Financial Corp increased its position in Exact Sciences by 4.9% in the fourth quarter. Truist Financial Corp now owns 19,304 shares of the medical research company’s stock worth $1,428,000 after buying an additional 908 shares in the last quarter.
National Bank of Canada FI raised its stake in Exact Sciences by 30.9% during the 4th quarter. National Bank of Canada FI now owns 848 shares of the medical research company’s stock worth $63,000 after acquiring an additional 200 shares during the period.
Private Advisor Group LLC lifted its holdings in Exact Sciences by 6.1% during the fourth quarter. Private Advisor Group LLC now owns 23,975 shares of the medical research company’s stock valued at $1,774,000 after purchasing an additional 1,379 shares in the last quarter.
Lincoln National Corp boosted its position in shares of Exact Sciences by 7.9% in the fourth quarter. Lincoln National Corp now owns 7,817 shares of the medical research company’s stock worth $578,000 after purchasing an additional 570 shares during the period.
Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Exact Sciences by 2.7% in the fourth quarter.
Charles Schwab Investment Management Inc. now owns 1,167,909 shares of the medical research company’s stock worth $86,402,000 after purchasing an additional 30,831 shares in the last quarter. 88.
82% of the stock is currently owned by hedge funds and other institutional investors. Wall Street Analysts Forecast Growth A number of research firms recently weighed in on EXAS. Jefferies Financial Group initiated coverage on shares of Exact Sciences in a research note on Monday, June 3rd.
They set a “buy” rating and a $75.00 target price on the stock. Stifel Nicolaus dropped their price objective on Exact Sciences from $100.
00 to $82.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. Benchmark decreased their target price on Exact Sciences from $91.
00 to $67.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. Wells Fargo & Company started coverage on Exact Sciences in a research note on Tuesday, August 27th.
They issued an “overweight” rating and a $75.00 price target for the company. Finally, BTIG Research reduced their price objective on shares of Exact Sciences from $80.
00 to $70.00 and set a “buy” rating on the stock in a research report on Wednesday, June 26th. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock.
According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $78.50. Exact Sciences Price Performance Exact Sciences stock opened at $59.
11 on Monday. Exact Sciences Co. has a 52-week low of $40.
62 and a 52-week high of $81.28. The company has a market cap of $10.
91 billion, a price-to-earnings ratio of -44.78 and a beta of 1.26.
The firm’s fifty day moving average is $52.94 and its 200 day moving average is $55.25.
The company has a quick ratio of 1.98, a current ratio of 2.17 and a debt-to-equity ratio of 0.
73. Exact Sciences ( NASDAQ:EXAS – Get Free Report ) last released its quarterly earnings results on Wednesday, July 31st. The medical research company reported ($0.
09) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.28.
Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%.
The company had revenue of $699.26 million during the quarter, compared to analyst estimates of $690.02 million.
During the same quarter last year, the business posted ($0.45) earnings per share. The firm’s revenue was up 12.
4% on a year-over-year basis. Sell-side analysts forecast that Exact Sciences Co. will post -0.
87 EPS for the current fiscal year. Exact Sciences Profile ( Free Report ) Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. Featured Stories Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co.
( NASDAQ:EXAS – Free Report ). Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
